Bio NC

Found 17,144 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

  5/22/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.

• Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

  5/22/2023

  Milestone Pharmaceuticals Inc. today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

• G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

  5/22/2023

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer.

• Tune Therapeutics Unveils Breakthrough Data Showing Stable and Durable Epigenetic Regulation in Non-Human Primates

  5/22/2023

  At the 26th Annual Meeting of the American Society of Gene & Cell Therapy, leading epigenetic editing company Tune Therapeutics showcased the power and potential of its TEMPO TM genetic tuning platform, by presenting data showing the stable repression of the PCSK9 gene and the effective reduction of LDL-cholesterol levels in non-human primates.

• Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

  5/19/2023

  Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting.

• IQVIA Announces Offering of Senior Secured Notes and Senior Notes

  5/18/2023

  IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).

• IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes

  5/18/2023

  IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 and $500,000,000 in aggregate principal amount of senior notes due 2030.

• Pfizer Prices $31,000,000,000 Debt Offering

  5/17/2023

  Pfizer Inc. announced the pricing of a debt offering consisting of eight tranches of notes.

• New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

  5/16/2023

  G1 Therapeutics, Inc., a commercial-stage oncology company, described recently presented real-world data that confirm a consistent risk of myelosuppressive events across patients with small cell lung cancer being treated with chemotherapy.

• Labcorp and Providence Expand Strategic Laboratory Relationship

  5/16/2023

  Labcorp, a leading global life sciences company, announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations.

• Syneos Health Leaders Recognized as PM360 2023 ELITE Award Recipients

  5/16/2023

  Syneos Health® announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience ; and Greg Christie, Chief Product Officer, StudyKIK, as recipients of its 9th Annual ELITE Awards.

• GeneCentric Therapeutics Initiates the Alamance Study – A Real-World Investigation of Bladder Cancer Patients Treated with FGFR Inhibitors and Other Standards of Care

  5/16/2023

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center.

• Alcami Appoints Laurent Boer as General Manager of Biostorage and Pharmaceutical Support Services.

  5/16/2023

  Alcami Corporation, a leading contract development and manufacturing organization, announced the appointment of Laurent Boer to the newly created position of General Manager, Biostorage and Pharma Services.

• IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

  5/16/2023

  IDEAYA Biosciences, Inc. announced that it has amended its clinical trial collaboration and supply agreements with Pfizer Inc. to support evaluation of darovasertib and crizotinib combination therapy in the company's planned Phase 2/3 registrational clinical trial in MUM and to continue support of the company's ongoing Phase 2 clinical trial in MUM.

• Bioventus Reports First Quarter Financial Results

  5/16/2023

  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

•  Pfizer Announces Proposed Notes Offering - May 15, 2023

  5/15/2023

  Pfizer Inc. announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd., has commenced a multi-series offering of senior unsecured notes.

• Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease

  5/15/2023

  Clinical ink, a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.

• NightHawk Biosciences Provides Q1 2023 Business Update

  5/15/2023

  NightHawk Biosciences, a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, provided strategic, financial, and operational updates for the quarter ended March 31, 2023.

• RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

  5/15/2023

  RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received a written notification from the Nasdaq Stock Market LLC dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued Nasdaq listing.